Kolexia
Fartoux Laetitia Gastro-entérologie
Fartoux Laetitia
Gastro-entérologie
Clinique Chirurg Alleray Labrouste
Paris, France
120 Activités
345 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome hépatocellulaire Carcinomes Tumeurs du foie Cholangiocarcinome Stéatose hépatique non alcoolique Tumeurs des voies biliaires Cirrhose du foie Maladies du foie Tumeurs des canaux biliaires

Collaborateurs

Voir plus
Rosmorduc Olivier
Rosmorduc Olivier
Hôpital Paul Brousse, Villejuif, France
Scatton Olivier
Scatton Olivier
Hôpital Saint-Antoine, Paris, France
Edeline Julien
Edeline Julien
Centre Eugène Marquis, Rennes, France
Faivre Sandrine
Faivre Sandrine
Hôpital Beaujon, Clichy, France

Industries

Voir plus
Ipsen
4 collaboration(s)
Dernière en 2021
Eisai
2 collaboration(s)
Dernière en 2020
Servier
1 collaboration(s)
Dernière en 2020
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224): A Phase 2 Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Advanced Hepatocellular Carcinoma (KEYNOTE-224)
Essai Clinique (Merck & Co.)   11 octobre 2023
SO-13 Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the open-label, phase 2 KEYNOTE-224 study
Abstract Book of the ESMO 24th World Congress on Gastrointestinal Cancer 2022, Barcelona, Spain, 29 June -2 July 2022   01 juin 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
European journal of cancer (Oxford, England : 1990)   29 mars 2022
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma: A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Essai Clinique (Eisai)   08 mars 2022
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
The lancet. Gastroenterology & hepatology   02 juin 2021
Dépistage du cancer colorectal et la stéatose hépatique - Dr. Laetitia Fartoux et Dr. Yves Benhamou
Youtube @ Meredith Santé   23 mars 2021
Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).
2020 Gastrointestinal Cancers Symposium   04 février 2020
RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro).
2020 Gastrointestinal Cancers Symposium   04 février 2020
Preoperative risk score for prediction of long-term outcomes after hepatectomy for intrahepatic cholangiocarcinoma: Report of a collaborative, international-based, external validation study
HPB : the official journal of the International Hepato Pancreato Biliary Association   01 janvier 2020
Preoperative risk score for prediction of long-term outcomes after hepatectomy for intrahepatic cholangiocarcinoma: Report of a collaborative, international-based, external validation study.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology   05 novembre 2019